Sciwind Biosciences to Present at EASD 2024 Annual Meeting

HANGZHOU, China and SAN FRANCISCO, Sept. 5, 2024 -- Sciwind Biosciences Co., Ltd., a biopharmaceutical company specializing in the development of innovative treatments for metabolic diseases, has announced positive findings from two clinical trials. The results will be presented at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting in Madrid, Spain, from September 9 – 13, 2024.

Sciwind will present outcomes from the Phase 3 study of their injectable drug ecnoglutide (XW003), targeting patients with type II diabetes mellitus, as well as findings from a Phase 1 study of an oral form of ecnoglutide (XW004) in both healthy and obese participants.

The presentation on XW003, titled "A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes," will be delivered by Dr. Susan Xu on September 12, 2024, from 10:45 AM to 12:15 PM CEST, during the session focused on incretin receptor agonists. This study highlights the efficacy and safety of ecnoglutide for diabetes management.

Dr. Mohammed Junaidi will present "Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide" on September 12, 2024, from 2:00 PM to 3:00 PM CEST. This session will delve into the initial safety and pharmacokinetic profile of the oral variant of ecnoglutide, showcasing its potential benefits and tolerability.

Ecnoglutide is a novel, cAMP signaling biased, long-acting GLP-1 peptide. It has been fine-tuned for enhanced biological activity and cost-effective production. This GLP-1 analog has shown promise not only for type 2 diabetes but also for obesity management. Clinical trials from Phase 1 to Phase 3 have demonstrated its effectiveness, safety, and tolerability.

Sciwind Biosciences is committed to discovering and developing groundbreaking therapies for metabolic diseases. Their pipeline is made up of potentially first-in-class and best-in-class drug candidates. These include the long-acting GLP-1 peptide analog XW003 (in Phase 3), the oral GLP-1 peptide analog XW004 (in Phase 1), an oral small molecule GLP-1 receptor agonist XW014 (in Phase 1), and novel amylin analogs currently in preclinical stages. Additionally, Sciwind has pioneered several proprietary technologies such as oral peptide and inhaled protein therapeutic delivery platforms, which have led to the identification of various promising drug candidates.

The presentation of these clinical trial outcomes at EASD 2024 signifies a major milestone for Sciwind Biosciences, as it underscores their potential in transforming the treatment landscape for metabolic diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!